MedTrace Logo

7T Amygdala and Citalopram Study

NCT06412315 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-02-21

No results posted yet for this study

Summary

The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds to emotional information.

Healthy participants will undergo medical and psychiatric health screening, after which they will be assigned to receive either a single dose of citalopram (20mg) or placebo, and undergo brain scanning (7T fMRI) whilst viewing emotional faces. Since the scan uses high field strength, the investigators will be able to see effects of citalopram on different subfields within the amygdala which will help to understand how citalopram might be working.

Conditions

  • Emotional Processing
  • Cognition
  • Mood Disorders
  • Depressive Disorder
  • Depression

Interventions

DRUG

Citalopram

Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.

DRUG

Placebo

Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-13
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06412315 on ClinicalTrials.gov